European Journal of Neurology,
Год журнала:
2024,
Номер
32(1)
Опубликована: Дек. 21, 2024
Abstract
Background
The
Brief
International
Cognitive
Assessment
for
Multiple
Sclerosis
(BICAMS)
has
been
validated
in
many
cross‐sectional
studies.
However,
longitudinal
data
on
BICAMS
subset
trajectories
and
their
correlation
with
disease
activity
during
follow‐up
are
scarce.
Objectives
We
aimed
to
(i)
assess
changes
MS
patients
initiating
high‐efficacy
disease‐modifying‐treatments
(DMTs),
(ii)
compare
these
based
maintenance
of
“no‐evidence‐of‐disease‐activity”
(NEDA‐3)
status
over
24
months,
(iii)
determine
baseline
clinical
parameters
predictive
cognitive
changes.
Methods
enrolled
101
(mean
age:40,45
±
11;
Relapsing–Remitting‐MS:81%)
highly‐effective‐DMTs.
Patients
underwent
Expanded
Disability
Status
Scale
(EDSS),
BICAMS,
Hospital
Anxiety
Depression
(HADS),
at
after
months.
Regression‐based
change
index
(RB‐CI)
had
used
evaluation
follow‐up.
Results
During
follow‐up,
78
(77.3%)
maintained
NEDA‐3
status.
Considering
a
90%
confidence
levels
RB‐CI,
12
(11.9%)
improved
SDMT,
13
(12.9%)
CVLT‐II
BVMT‐R;
while
7
(6.9%)
were
classified
as
worsened
11
(10.9%)
8
(7.9%)
BVMT‐R.
SDMT
scores
significantly
the
entire
group
(
p
=
0.003)
maintaining
<
0.001).
multivariable
regression
model
assessing
improvement
n
12;
z
1.65),
was
significant
explained
21%
variance
0.038;
Nagelkerke
R
2
0.212).
Lower
EDSS
proved
be
an
independent
predictor
reliable
0.027)
our
sample.
Conclusions
Our
findings
showed
that
early
control—especially
low
disability—may
yield
benefits
even
terms
performance.
npj Digital Medicine,
Год журнала:
2023,
Номер
6(1)
Опубликована: Окт. 19, 2023
Modern
management
of
MS
targets
No
Evidence
Disease
Activity
(NEDA):
no
clinical
relapses,
magnetic
resonance
imaging
(MRI)
disease
activity
and
disability
worsening.
While
MRI
is
the
principal
tool
available
to
neurologists
for
monitoring
clinically
silent
and,
where
appropriate,
escalating
treatment,
standard
radiology
reports
are
qualitative
may
be
insensitive
development
new
or
enlarging
lesions.
Existing
quantitative
neuroimaging
tools
lack
adequate
validation.
In
397
multi-center
scan
pairs
acquired
in
routine
practice,
we
demonstrate
superior
case-level
sensitivity
a
integrated
AI-based
over
(93.3%
vs
58.3%),
relative
consensus
ground
truth,
with
minimal
loss
specificity.
We
also
equivalence
AI-tool
core
trial
lab
lesion
brain
volumetric
measures,
including
percentage
volume
(PBVC),
an
accepted
biomarker
neurodegeneration
(mean
PBVC
-0.32%
-0.36%,
respectively),
whereas
even
severe
atrophy
(>0.8%
loss)
was
not
appreciated
reports.
Finally,
additionally
embeds
meaningful,
experiential
comparator
that
returns
relevant
patient
centile
burden,
revealing,
our
cohort,
inconsistencies
descriptors
used
image
quantitation
enhances
accuracy
of,
value-adds
to,
reporting.
Scaled
deployment
these
will
open
path
precision
patients
MS.
Frontiers in Neurology,
Год журнала:
2024,
Номер
15
Опубликована: Апрель 18, 2024
Recent
years
have
seen
the
emergence
of
disease-modifying
therapies
in
multiple
sclerosis
(MS),
such
as
anti-cluster
differentiation
20
(anti-CD20)
monoclonal
antibodies,
aiming
to
modulate
immune
response
and
effectively
manage
MS.
However,
relationship
between
anti-CD20
treatments
immunoglobulin
G
(IgG)
levels,
particularly
development
hypogammaglobulinemia
subsequent
infection
risks,
remains
a
subject
scientific
interest
variability.
We
aimed
investigate
intricate
connection
MS
treatments,
changes
IgG
associated
risk
infections.
Multiple Sclerosis Journal,
Год журнала:
2024,
Номер
30(11-12), С. 1468 - 1478
Опубликована: Авг. 28, 2024
Substantial
physical-disability
worsening
in
relapsing-remitting
multiple
sclerosis
(RRMS)
occurs
outside
of
clinically
recorded
relapse.
This
phenomenon,
termed
progression
independent
relapse
activity
(PIRA),
is
yet
to
be
established
for
cognitive
decline.
Annals of Clinical and Translational Neurology,
Год журнала:
2024,
Номер
11(8), С. 2008 - 2015
Опубликована: Июль 5, 2024
No
direct
comparisons
of
the
effect
natalizumab
and
ocrelizumab
on
progression
independent
relapse
activity
(PIRA)
relapse-associated
worsening
(RAW)
events
are
currently
available.
We
aimed
to
compare
risk
achieving
first
6
months
confirmed
PIRA
RAW
irreversible
Expanded
Disability
Status
Scale
(EDSS)
4.0
6.0
in
a
cohort
naïve
patients
treated
with
or
from
Italian
Multiple
Sclerosis
Register.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(24), С. 17151 - 17151
Опубликована: Дек. 5, 2023
Multiple
sclerosis
(MS),
neuromyelitis
optica
spectrum
disorder
(NMOSD),
and
myelin
oligodendrocytes
glycoprotein-antibody
disease
(MOGAD)
are
distinct
autoimmune
demyelinating
disorders
characterized
by
varying
clinical
pathological
characteristics.
While
the
precise
origins
of
these
diseases
remain
elusive,
a
combination
genetic
environmental
factors,
including
viral
elements,
have
been
suggested
as
potential
contributors
to
their
development.
Our
goal
was
assess
occurrence
antibodies
against
pathogenic
peptides
associated
with
Epstein-Barr
virus
(EBV)
human
endogenous
retrovirus-W
(HERV-W)
in
serum
samples
obtained
from
Japanese
individuals
diagnosed
MS,
NMOSD,
MOGAD
make
comparisons
group
healthy
controls
(HCs).
We
conducted
retrospective
analysis
involving
114
participants,
comprising
MS
(34),
NMOSD
(20),
HCs
(40).
These
were
tested
using
peptide-based
enzyme-linked
immunosorbent
assay.
A
marked
increase
antibody
response
EBV
nuclear
antigen
1
(EBNA1)386-405
observed
patients,
compared
HCs.
Notably,
we
correlation
between
EBNA1386-405
HERV-W486-504
subset
antibody-positive
patients.
findings
emphasize
involvement
pathogenesis
potentially
MOGAD,
suggesting
its
role
reactivation
HERV-W.
Multiple Sclerosis Journal,
Год журнала:
2024,
Номер
30(10), С. 1309 - 1321
Опубликована: Июль 31, 2024
To
summarize
the
current
evidence
on
relapse-associated
worsening
(RAW)
and
progression
independent
of
relapse
activity
(PIRA)
through
a
quantitative
synthesis
real-world
studies.
Journal of Neuroinflammation,
Год журнала:
2024,
Номер
21(1)
Опубликована: Авг. 21, 2024
Tumor
necrosis
factor
(TNF)
is
a
pleiotropic
cytokine
regulating
many
physiological
and
pathological
immune-mediated
processes.
Specifically,
it
has
been
recognized
as
an
essential
pro-inflammatory
implicated
in
multiple
sclerosis
(MS)
pathogenesis
progression.
MS
chronic
disease
of
the
central
nervous
system,
characterized
by
multifocal
acute
inflammatory
demyelination
white
grey
matter,
along
with
neuroaxonal
loss.
A
recent
concept
field
research
disability
resulting
from
Progression
Independent
Relapse
Activity
(PIRA).
PIRA
recognizes
that
accumulation
since
early
phase
can
occur
independently
relapse
activity
overcoming
traditional
dualistic
view
either
relapsing-inflammatory
or
progressive-neurodegenerative
disease.
Several
studies
have
demonstrated
upregulation
TNF
expression
both
active
brain
lesions.
Additionally,
elevated
levels
observed
serum
cerebrospinal
fluid
patients.
appears
to
play
significant
role
maintaining
intrathecal
inflammation,
promoting
axonal
damage
neurodegeneration,
consequently
contributing
progression
accumulation.
In
summary,
this
review
highlights
current
understanding
its
receptors
progression,
specifically
focusing
on
relatively
unexplored
condition.
Further
area
holds
promise
for
potential
therapeutic
interventions
targeting
mitigate
Multiple Sclerosis Journal,
Год журнала:
2024,
Номер
30(11-12), С. 1402 - 1404
Опубликована: Авг. 28, 2024
Progression
independent
of
relapse
activity
(PIRA)
has
been
recently
proposed
in
multiple
sclerosis
(MS)
as
a
model
identifying
continuous
silent
progression
disability
without
the
manifestation
new
clinical
and
magnetic
resonance
imaging
(MRI)
events
that
contribute
to
MS
worsening.
Despite
evidence
suggesting
manifestations
often
affect
cognitive
functioning
importance
neuropsychological
monitoring
over
time,
attention
is
lacking,
PIRA
concept
does
not
include
measure
function.
In
this
personal
viewpoint,
we
highlight
need
cognition
have
more
comprehensive
understanding
patients
with
MS.
